Sinonasal disease among patients with primary ciliary dyskinesia: an international study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
12
12
2022
accepted:
21
03
2023
medline:
25
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Sinonasal symptoms are a common feature of primary ciliary dyskinesia (PCD); however, literature about their severity and frequency, particularly during the life course, is scarce. Using baseline data from the Ear, nose and throat (ENT) Prospective International Cohort of PCD patients, we describe sinonasal disease in PCD. We included participants who had a routine sinonasal examination during which they completed a symptoms questionnaire. We compared frequency of reported symptoms and examination findings among children and adults, and identified characteristics potentially associated with higher risk of sinonasal disease using ordinal regression. 12 centres contributed 384 participants; median age was 16 years (IQR 9-22), and 54% were male. Chronic nasal problems were the most common feature, reported by 341 (89%). More adults (33; 24%) than children (10; 4%) described hyposmia. Quality of life was moderately affected by rhinosinusitis among 136 participants with completed SNOT-22 questionnaires (median score 31; IQR 23-45). Examinations revealed nasal polyps among 51 of 345 participants (15%) and hypertrophic inferior nasal turbinates among 127 of 341 participants (37%). Facial pain was detected in 50 of 342 participants (15%). Nasal polyps, hypertrophic turbinates, deviated septum and facial pain were found more commonly in adults than children. The only characteristic associated with higher risk of sinonasal disease was age 10 years and older. Based on our findings, regular sinonasal examinations are relevant for patients with PCD of all ages. There is a need for improved management of sinonasal disease supported by evidence-based guidelines.
Sections du résumé
Background
UNASSIGNED
Sinonasal symptoms are a common feature of primary ciliary dyskinesia (PCD); however, literature about their severity and frequency, particularly during the life course, is scarce. Using baseline data from the Ear, nose and throat (ENT) Prospective International Cohort of PCD patients, we describe sinonasal disease in PCD.
Methods
UNASSIGNED
We included participants who had a routine sinonasal examination during which they completed a symptoms questionnaire. We compared frequency of reported symptoms and examination findings among children and adults, and identified characteristics potentially associated with higher risk of sinonasal disease using ordinal regression.
Results
UNASSIGNED
12 centres contributed 384 participants; median age was 16 years (IQR 9-22), and 54% were male. Chronic nasal problems were the most common feature, reported by 341 (89%). More adults (33; 24%) than children (10; 4%) described hyposmia. Quality of life was moderately affected by rhinosinusitis among 136 participants with completed SNOT-22 questionnaires (median score 31; IQR 23-45). Examinations revealed nasal polyps among 51 of 345 participants (15%) and hypertrophic inferior nasal turbinates among 127 of 341 participants (37%). Facial pain was detected in 50 of 342 participants (15%). Nasal polyps, hypertrophic turbinates, deviated septum and facial pain were found more commonly in adults than children. The only characteristic associated with higher risk of sinonasal disease was age 10 years and older.
Conclusions
UNASSIGNED
Based on our findings, regular sinonasal examinations are relevant for patients with PCD of all ages. There is a need for improved management of sinonasal disease supported by evidence-based guidelines.
Identifiants
pubmed: 37228283
doi: 10.1183/23120541.00701-2022
pii: 00701-2022
pmc: PMC10204851
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: P. Latzin received grants or honoraria for participation in data safety monitoring boards or advisory boards from Vertex, Vifor, OM Pharma, Polyphor, Santhera (DMC) and Sanofi Aventis within the last 36 months. J. Roehmel received grants and clinical study remuneration from Vertex, INSMED, Medical Research Council/UK, BMBF and Mukoviszidose Institut. All other authors have nothing to declare.
Références
Am J Rhinol Allergy. 2021 Jan;35(1):72-76
pubmed: 32551925
J Clin Med. 2020 Sep 04;9(9):
pubmed: 32899853
Expert Rev Respir Med. 2017 Oct;11(10):779-790
pubmed: 28745925
Eur Respir J. 2017 Jan 4;49(1):
pubmed: 27836958
Arch Dis Child. 2014 Sep;99(9):850-6
pubmed: 24771309
Eur Respir J. 2016 Oct;48(4):1081-1095
pubmed: 27492829
BMJ Open. 2021 Oct 11;11(10):e051433
pubmed: 34635525
J Clin Med. 2019 May 07;8(5):
pubmed: 31067752
Acta Otolaryngol. 2015 Jan;135(1):58-63
pubmed: 25370419
Am J Med Genet C Semin Med Genet. 2022 Mar;190(1):89-101
pubmed: 35343062
Paediatr Respir Rev. 2016 Mar;18:33-8
pubmed: 26898410
Dan Med J. 2017 May;64(5):
pubmed: 28552099
Eur Arch Otorhinolaryngol. 2011 Mar;268(3):383-8
pubmed: 20652291
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
ERJ Open Res. 2022 Apr 11;8(2):
pubmed: 35415187
J Aerosol Med. 2006 Spring;19(1):110-5
pubmed: 16551222
Otolaryngol Head Neck Surg. 2022 Mar;166(3):540-547
pubmed: 34154450
Eur Respir J. 2016 Apr;47(4):1103-12
pubmed: 26917608
J Paediatr Child Health. 2015 Jul;51(7):722-6
pubmed: 25510893
Auris Nasus Larynx. 2022 Apr;49(2):248-257
pubmed: 34454779
Ann Allergy Asthma Immunol. 2013 Oct;111(4):246-251.e2
pubmed: 24054358
J Clin Med. 2019 Sep 19;8(9):
pubmed: 31546861
Arch Dis Child. 2020 Aug;105(8):724-729
pubmed: 32156696
Am J Respir Crit Care Med. 2019 Jan 15;199(2):190-198
pubmed: 30067075
Clin Chest Med. 2022 Mar;43(1):127-140
pubmed: 35236553
ERJ Open Res. 2020 Feb 10;6(1):
pubmed: 32055632
Front Pediatr. 2017 Mar 03;5:44
pubmed: 28316969
Laryngoscope. 2023 Feb;133(2):248-254
pubmed: 35312075
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Acta Otolaryngol. 2000 Jan;120(1):72-6
pubmed: 10779190
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32060067
Appl Clin Genet. 2017 Sep 19;10:67-74
pubmed: 29033599
Eur Respir J. 2022 Oct 20;60(4):
pubmed: 35301251
Int J Public Health. 2021 Dec 15;66:1604277
pubmed: 34975364
Int Forum Allergy Rhinol. 2013 Dec;3(12):986-91
pubmed: 24124045
Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):32-8
pubmed: 22157161
Eur Respir J. 2021 Aug 5;58(2):
pubmed: 33833032
Int Forum Allergy Rhinol. 2022 Mar;12(3):278-285
pubmed: 34510792